Featured

Trimb Healthcare AB has acquired a portfolio of well-established European OTC products from Cilag GmbH International and Janssen Pharmaceutica NV. The products, which include Pevaryl®, Fungoral®, Gyno-Pevaryl® and Epi-Pevaryl®, are based on the anti-fungal substances econazole and ketoconazole and are...

IBM announced that CipherHealth, a SaaS healthcare provider, has deployed IBM Power Systems™ infrastructure to run its technology platform that helps healthcare providers reduce re-admissions and improve the patient experience by providing effective patient engagement from pre-hospitalization through to...

NetDirector, a cloud-based data exchange and integration platform, has engaged in a rapid expansion strategy in the healthcare industry over the last few years. Recently, the Integration-Platform-as-a-Service (iPaaS) has completed implementation with American Health Imaging, a regional network of...

Resverlogix Corp announced that it has received approval from Health Canada, Therapeutic Products Directorate, to proceed with a clinical trial with its lead compound apabetalone in patients with Fabry disease. Donald McCaffrey, President and CEO, stated, "We are extremely pleased...

Mission Regional Medical Center in Mission, Texas and Prime Healthcare Foundation have signed a definitive agreement for the acquisition of the 297-bed community hospital. The agreement includes a commitment from Prime Healthcare Foundation to maintain Mission Regional as an acute...

ERT, a global data and technology company that minimizes uncertainty and risk in clinical trials announced the acquisition of ImageIQ, originally established as Cleveland Clinic’s Biomedical Imaging and Analysis Center. The acquisition enables ERT to offer advanced, end-to-end clinical...

ContraVir Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced it is developing a second-generation formulation of TXL™, the Company’s proprietary liver-targeting prodrug of the antiviral agent tenofovir for treating chronic HBV.    Subsequent...